Grifols (GIKLY) Change in Cash (2010 - 2016)
Grifols (GIKLY) reported Change in Cash of -$5.9 million for Q4 2016, up 95.67% on a YoY basis from -$3.0 million in Q1 2016, and up 99.09% quarter-over-quarter from -$644.6 million in Q3 2016.
Grifols (GIKLY) Change in Cash (2010 - 2016) Analysis & Trends
Grifols has reported Change in Cash for 6 years, with the latest figure at -$5.9 million in Q4 2016.
- For the quarter ending Q4 2016, Change in Cash rose 95.67% year-over-year to -$5.9 million; the trailing twelve-month figure through Dec 2016 stood at -$901.1 million (down 1520.11% YoY), and the FY2025 full-year result was -$180.4 million, down 137.44% from the prior year.
- Change in Cash for Q4 2016 stood at -$5.9 million, up from -$644.6 million in the prior quarter.
- The five-year high for Change in Cash was $631.9 million in Q2 2015, with the low at -$644.6 million in Q3 2016.
- Historically, Change in Cash has averaged -$29.8 million across 4 years, with a median of -$5.9 million in 2016.
- Annual changes were most pronounced in 2013 — Change in Cash soared 39081.59% — and 2016, when it tumbled 462.04%.
- Grifols' Change in Cash stood at $94.3 million in 2012, then slipped by 4.33% to $90.2 million in 2013, then slumped by 250.57% to -$135.9 million in 2015, then surged by 95.67% to -$5.9 million in 2016.
- The last three Change in Cash figures came in at -$5.9 million (Q4 2016), -$644.6 million (Q3 2016), and -$135.9 million (Q4 2015), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -71.45 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | -1.99 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 1.98 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 4.16 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -9.29 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 2.91 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 65.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 563.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -635.00 Mn |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | -5.89 Mn |
| Sep 30, 2016 | -644.62 Mn |
| Dec 31, 2015 | -135.86 Mn |
| Sep 30, 2015 | -114.69 Mn |
| Jun 30, 2015 | 631.90 Mn |
| Mar 31, 2015 | -317.90 Mn |
| Mar 31, 2013 | 90.23 Mn |
| Dec 31, 2012 | 94.32 Mn |
| Sep 30, 2012 | 107.50 Mn |
| Jun 30, 2012 | -33.56 Mn |
| Mar 31, 2012 | 230,290.61 |
| Dec 31, 2011 | 239.85 Mn |
| Sep 30, 2011 | -109.46 Mn |
| Jun 30, 2011 | 86.63 Mn |
| Mar 31, 2011 | -81.89 Mn |
| Dec 31, 2010 | -20.16 Mn |
| Sep 30, 2010 | -123.50 Mn |